It is indicated to treat severe infections. But the Italian Medicines Agency intervened to stem the dangers.
Drugs have been withdrawn from the market in recent weeks. The Medicines Agency, in fact, is always very attentive to everyone’s health. In this case, some batches of a well-known drug have been withdrawn. Here’s what it is.
We are talking about a drug used to treat heart disease and a common antibiotic. Atenolol-Mepha is very suitable for high blood pressure. The Swiss pharmaceutical company Mepha Pharma AG has ordered the recall of one of the batches of the product as it contains slightly less of the active ingredient atenolol.
More or less in the same period in agreement with the Ministry of Health, the veterinary medicine Ronaxan, an antibiotic used in dogs and cats, has been withdrawn. The Boehringer Ingelheim Animal Health Italia company announces that the withdrawal āis due to an update of the package leafletā. Furthermore, the withdrawal refers exclusively to the distribution chain.
“We wish to inform all consumers that the product, which they may have at home, is safe and effective and can continue to use it as indicated by their veterinarian” reads a note. But now comes the withdrawal of another widely used drug.
Other drug withdrawn
But now comes the withdrawal of another widely used drug. The latter, in fact, is indicated for treating even serious infections and, therefore, it is recommended when the situation is already compromised and the imminent danger requires a quick, timely and decisive intervention.
It is an important drug, which treats, for example, urinary tract infections, septicemias, bone and skin infections, but also those of the gastrointestinal tract. Also used against meningitis and eye infections.
Its active ingredient is Tobramycin, an antibiotic used by many people in our country. With a specific provision, the Italian Medicines Agency (AIFA) has ordered the withdrawal of some batches of an antibiotic. Specifically, it is the medicinal product TOBRAMICIN IBI 100 mg / 2 ml vials, AIC 033973013, lot n. 0013167 with expiry 04/2023 and TOBRAMICIN IBI ampoules 150 mg / 2 ml, AIC 033973025, lot n. 0013170 with expiry 04/2023 of the company IBI ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI SPA.
According to the findings, a quality problem was found in the antibiotic, which, therefore, can cause serious consequences for those who take it. The AIFA warning is not to take the antibiotic and to return the offending package to a pharmacy. The purchase may have been in the form of eye drops, powders, ophthalmic ointments, tablets or solutions to be administered intravenously or intramuscularly.